JP5366817B2 - アリールスルホンアミド化合物 - Google Patents

アリールスルホンアミド化合物 Download PDF

Info

Publication number
JP5366817B2
JP5366817B2 JP2009537374A JP2009537374A JP5366817B2 JP 5366817 B2 JP5366817 B2 JP 5366817B2 JP 2009537374 A JP2009537374 A JP 2009537374A JP 2009537374 A JP2009537374 A JP 2009537374A JP 5366817 B2 JP5366817 B2 JP 5366817B2
Authority
JP
Japan
Prior art keywords
heteroaryl
aryl
compound
alkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009537374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010510237A5 (enExample
JP2010510237A (ja
Inventor
ジョナサン ベイルドン バール，
ギヨーム ローラン レッセン，
ブラッド エドマンド スリーブズ，
ウェイン ジェイ． フェアブラザー，
ジョン エー． フライゲール，
マイケル エフ．ティ． コーラー，
Original Assignee
ジェネンテック， インコーポレイテッド
ザ ウォルター アンド イライザ ホール インスティチュート オブ メディカル リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック， インコーポレイテッド, ザ ウォルター アンド イライザ ホール インスティチュート オブ メディカル リサーチ filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2010510237A publication Critical patent/JP2010510237A/ja
Publication of JP2010510237A5 publication Critical patent/JP2010510237A5/ja
Application granted granted Critical
Publication of JP5366817B2 publication Critical patent/JP5366817B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2009537374A 2006-11-15 2007-11-15 アリールスルホンアミド化合物 Active JP5366817B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85931506P 2006-11-15 2006-11-15
US60/859,315 2006-11-15
PCT/US2007/084873 WO2008061208A2 (en) 2006-11-15 2007-11-15 Arylsulfonamide compounds

Publications (3)

Publication Number Publication Date
JP2010510237A JP2010510237A (ja) 2010-04-02
JP2010510237A5 JP2010510237A5 (enExample) 2011-01-27
JP5366817B2 true JP5366817B2 (ja) 2013-12-11

Family

ID=39276199

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009537374A Active JP5366817B2 (ja) 2006-11-15 2007-11-15 アリールスルホンアミド化合物

Country Status (9)

Country Link
US (1) US8168645B2 (enExample)
EP (1) EP2094672B1 (enExample)
JP (1) JP5366817B2 (enExample)
CN (1) CN101535280B (enExample)
AU (1) AU2007319209B2 (enExample)
CA (1) CA2666837C (enExample)
ES (1) ES2423029T3 (enExample)
NZ (1) NZ577442A (enExample)
WO (1) WO2008061208A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
EA019156B1 (ru) 2008-02-01 2014-01-30 Такеда Фармасьютикал Компани Лимитед Производные оксима в качестве ингибиторов hsp90
EP2279174A2 (en) * 2008-05-21 2011-02-02 Genentech, Inc. Arylsulfonamide compounds, compositions and methods of use
US8168784B2 (en) * 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
JP2013504536A (ja) * 2009-09-10 2013-02-07 ノバルティス アーゲー 癌の処置のためのｂｃｌ−２ファミリータンパク質阻害剤としてのスルホンアミド類
TWI535712B (zh) * 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
BR112014014529A2 (pt) 2011-12-13 2019-09-24 Buck Inst For Res On Aging métodos para melhorar terapias médicas
KR20140104047A (ko) 2011-12-23 2014-08-27 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
CA2859862A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
EP3099380B1 (en) 2014-01-28 2021-08-11 Buck Institute for Research on Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
CN111801327B (zh) 2018-01-10 2024-02-09 里科瑞尔姆Ip控股有限责任公司 苯甲酰胺化合物
CN108276395B (zh) * 2018-02-09 2021-02-26 合肥华方医药科技有限公司 一种多沙唑嗪杂质的制备方法
CN108570039B (zh) * 2018-04-25 2022-09-23 上海美迪西生物医药股份有限公司 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用
CN109851535A (zh) * 2019-01-30 2019-06-07 天津现代职业技术学院 一种制备4-氟-3-(三氟甲磺酰基)苯磺酰胺的方法
CN113248415B (zh) * 2021-05-26 2022-08-09 苏州正永生物医药有限公司 一种abt-737关键中间体的制备方法以及abt-737的制备方法
TW202334089A (zh) 2021-11-02 2023-09-01 美商夫雷爾醫療公司 Ｐｐａｒｇ反向激動劑及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720338B2 (en) * 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
CA2479362C (en) * 2002-03-21 2011-01-04 Abbott Laboratories N-sulfonylurea apoptosis promoters
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) * 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7642260B2 (en) * 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
EP1686121B1 (en) 2003-11-20 2010-02-10 Mitsubishi Gas Chemical Company, Inc. Liquid cyclohexane-tricarboxylic acid anhydride
WO2005117543A2 (en) * 2004-05-26 2005-12-15 Abbott Laboratories N-sulfonylcarboximidamide apoptosis promoters
US8557812B2 (en) * 2004-08-20 2013-10-15 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof
US20060122247A1 (en) * 2004-12-08 2006-06-08 Solvay Pharmaceuticals B.V. Aryloxyethylamine and phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
PL1888550T3 (pl) * 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy

Also Published As

Publication number Publication date
CA2666837C (en) 2015-01-13
ES2423029T3 (es) 2013-09-17
EP2094672B1 (en) 2013-05-29
JP2010510237A (ja) 2010-04-02
WO2008061208A3 (en) 2008-07-03
CN101535280B (zh) 2012-06-27
CN101535280A (zh) 2009-09-16
AU2007319209A1 (en) 2008-05-22
US8168645B2 (en) 2012-05-01
NZ577442A (en) 2012-02-24
HK1134283A1 (en) 2010-04-23
US20100056517A1 (en) 2010-03-04
AU2007319209B2 (en) 2012-04-19
CA2666837A1 (en) 2008-05-22
WO2008061208A2 (en) 2008-05-22
EP2094672A2 (en) 2009-09-02

Similar Documents

Publication Publication Date Title
JP5366817B2 (ja) アリールスルホンアミド化合物
ES2967983T3 (es) Compuestos
ES2914099T3 (es) Inhibidores novedosos de ULK1 y métodos de uso de los mismos
ES2729424T3 (es) Inhibidores de Rho cinasa
CN108834412B (zh) 嘧啶及其变体、及其用途
US20100197711A1 (en) Benzothiazole compounds
ES2888298T3 (es) Compuestos de C5-anilinoquinazolina y su uso en el tratamiento de cáncer
WO2017101803A1 (zh) 一种新型egfr和alk激酶的双重抑制剂
TWI473792B (zh) New quinoline compounds and their use
AU2019218187B2 (en) Dioxinoquinoline compounds, preparation method and uses thereof
TW201620882A (zh) 作為ｅｇｆｒ抑制劑的苯基取代的三嗪類化合物及其應用
AU2018226922B2 (en) Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof
WO2018153293A1 (zh) 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用
JP2014520860A (ja) タンキラーゼ阻害剤として使用するための４−オキソ−３，５，７，８−テトラヒドロ−４Ｈ−ピラノ｛４，３−ｄ｝ピルミニジニル化合物
CN105829285A (zh) 喹唑啉酮和异喹啉酮衍生物
CA2871453A1 (en) Quinazolinedione derivative
Altıntop et al. Synthesis and evaluation of a series of 1, 3, 4-thiadiazole derivatives as potential anticancer agents
ES2887261T3 (es) Compuestos de fenoxiquinazolina y su uso para tratar el cáncer
CN105585565B (zh) 含2-苯胺基-4-噻唑基吡啶衍生物及其制法和药物组合物与用途
WO2019170088A1 (zh) 一种噁嗪并喹唑啉与噁嗪并喹啉类化合物及其制备方法和应用
ES2936482T3 (es) Agentes antiinfecciosos
ES2328929T3 (es) Dihidroquinazolinas 2-sustituidas.
Brzozowski et al. Carbonic anhydrase inhibitors. Regioselective synthesis of novel series 1-substituted 1, 4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII
CN111662275B (zh) 苯磺酰胺类idh突变体抑制剂、其制备方法和用途
JP7022454B2 (ja) ジオキシノキノリン系化合物、その調製方法および使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130424

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130724

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130820

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130910

R150 Certificate of patent or registration of utility model

Ref document number: 5366817

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250